[go: up one dir, main page]

AR129995A1 - ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES - Google Patents

ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES

Info

Publication number
AR129995A1
AR129995A1 ARP230101920A ARP230101920A AR129995A1 AR 129995 A1 AR129995 A1 AR 129995A1 AR P230101920 A ARP230101920 A AR P230101920A AR P230101920 A ARP230101920 A AR P230101920A AR 129995 A1 AR129995 A1 AR 129995A1
Authority
AR
Argentina
Prior art keywords
cdr
seq
steap1
antigen
asp
Prior art date
Application number
ARP230101920A
Other languages
Spanish (es)
Inventor
Meredith Carroll Hazen
Isidro Hotzel
Julien Lafrance-Vanasse
Gabriele Maria Schaefer
Dhaya Seshasayee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR129995A1 publication Critical patent/AR129995A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona moléculas de unión al antígeno monoespecíficas y multiespecíficas y composiciones de estas. La invención también incluye métodos para tratar una enfermedad o trastorno, tal como cáncer, métodos para inhibir el crecimiento tumoral, kits para su uso con el uno o más métodos. Reivindicación 1: Una molécula de unión al antígeno multiespecífica que comprende: (A) un primer dominio de unión al antígeno que se une a STEAP1 y comprende una región variable de la cadena pesada (VH) anti-STEAP1 que comprende CDR-H1, CDR-H2 y CDR-H3 de una secuencia VH seleccionada de SEQ ID Nº 7, 17 - 25, 30 - 34, 38 y 68; y una región variable de la cadena liviana (VL) anti-STEAP1 que comprende CDR-L1, CDR-L2 y CDR-L3 de una secuencia VL seleccionada de SEQ ID Nº 8, 26 - 29, 39 y 69; y (B) un segundo dominio de unión al antígeno que se une a un receptor de linfocitos T. Reivindicación 2: Una molécula de unión al antígeno multiespecífica que comprende: (A) un primer dominio de unión al antígeno que se une a STEAP1 y comprende una región variable de la cadena pesada (VH) anti-STEAP1 que comprende CDR-H1, CDR-H2 y CDR-H3; y una región variable de la cadena liviana (VL) anti-STEAP1 que comprende CDR-L1, CDR-L2 y CDR-L3; en donde CDR-H1 comprende Xaa¹Xaa²YMA (SEQ ID Nº 35); en donde Xaa¹ es Asp (D) o Asn (N); y Xaa² es His (H), Tyr (Y) o Phe (F); CDR-H2 comprende YIXaa³YDGXaa⁴Xaa⁵TXaa⁶YGDSVKG (SEQ ID Nº 36); en donde Xaa³ es Asp (D) o Ser (S); Xaa⁴ es Gly (G), Asp (D) o Leu (L); Xaa⁵ es Ser (S), Asp (D) o Asn (N); y Xaa⁶ es Ser (S) o Tyr (Y); y CDR-H3 comprende RSGXaa⁷YHVGYAMXaa⁸Xaa⁹ (SEQ ID Nº 37); en donde Xaa⁷ es Phe (F) o Tyr (Y); Xaa⁸ es Asn (N) o Asp (D); y Xaa⁹ es Ala (A) o Gly (G); CDR-L1 comprende la secuencia de aminoácidos de SEQ ID Nº 4; CDR-L2 comprende la secuencia de aminoácidos de SEQ ID Nº 5; y CDR-L3 comprende la secuencia de aminoácidos de SEQ ID Nº 6; y (B) un segundo dominio de unión al antígeno que se une a un receptor de linfocitos T. Reivindicación 95: Un anticuerpo que comprende un primer dominio de unión al antígeno que se une a STEAP1 humano en uno o más residuos seleccionados de Ser101, His102, Gln103 y Lys281, en donde las posiciones de los residuos 101, 102, 103 y 281 corresponden a las posiciones 101, 102, 103 y 281 indicadas en SEQ ID Nº 65. Reivindicación 142: Uso de la molécula de unión al antígeno multiespecífica de acuerdo con cualquiera de las reivindicaciones 1 - 54, la molécula de unión al antígeno de acuerdo con cualquiera de las reivindicaciones 55 - 94, o el anticuerpo de acuerdo con cualquiera de las reivindicaciones 95 - 110 en la elaboración de un medicamento para el tratamiento o retraso de la progresión de cáncer que expresa STEAP1 en un sujeto que lo necesita, opcionalmente para el tratamiento o retraso de la progresión de cáncer de próstata o sarcoma de Ewing.The present invention provides monospecific and multispecific antigen binding molecules and compositions thereof. The invention also includes methods of treating a disease or disorder, such as cancer, methods of inhibiting tumor growth, kits for use with the one or more methods. Claim 1: A multispecific antigen binding molecule comprising: (A) a first antigen binding domain that binds STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1, CDR-H2 and CDR-H3 of a VH sequence selected from SEQ ID NOs: 7, 17-25, 30-34, 38 and 68; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1, CDR-L2 and CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26-29, 39 and 69; and (B) a second antigen-binding domain that binds to a T cell receptor. Claim 2: A multispecific antigen-binding molecule comprising: (A) a first antigen-binding domain that binds STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1, CDR-H2 and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1, CDR-L2 and CDR-L3; wherein CDR-H1 comprises Xaa¹Xaa²YMA (SEQ ID NO: 35); where Xaa¹ is Asp (D) or Asn (N); and Xaa² is His (H), Tyr (Y) or Phe (F); CDR-H2 comprises YIXaa³YDGXaa⁴Xaa⁵TXaa⁶YGDSVKG (SEQ ID NO: 36); where Xaa³ is Asp (D) or Ser (S); Xaa⁴ is Gly (G), Asp (D) or Leu (L); Xaa⁵ is Ser (S), Asp (D) or Asn (N); and Xaa⁶ is Ser (S) or Tyr (Y); and CDR-H3 comprises RSGXaa⁷YHVGYAMXaa⁸Xaa⁹ (SEQ ID NO: 37); where Xaa⁷ is Phe (F) or Tyr (Y); Xaa⁸ is Asn (N) or Asp (D); and Xaa⁹ is Ala (A) or Gly (G); CDR-L1 comprises the amino acid sequence of SEQ ID No. 4; CDR-L2 comprises the amino acid sequence of SEQ ID No. 5; and CDR-L3 comprises the amino acid sequence of SEQ ID No. 6; and (B) a second antigen-binding domain that binds to a T cell receptor. Claim 95: An antibody comprising a first antigen-binding domain that binds human STEAP1 at one or more residues selected from Ser101, His102, Gln103 and Lys281, wherein the positions of residues 101, 102, 103 and 281 correspond to positions 101, 102, 103 and 281 indicated in SEQ ID NO: 65. Claim 142: Use of the multispecific antigen-binding molecule according to any of claims 1 - 54, the antigen-binding molecule according to any of claims 55 - 94, or the antibody according to any of claims 95 - 110 in the manufacture of a medicament for the treatment or delay of the progression of cancer expressing STEAP1 in a subject in need thereof, optionally for the treatment or delay of progression of prostate cancer or Ewing sarcoma.

ARP230101920A 2022-07-22 2023-07-21 ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES AR129995A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263391568P 2022-07-22 2022-07-22

Publications (1)

Publication Number Publication Date
AR129995A1 true AR129995A1 (en) 2024-10-23

Family

ID=87580257

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101920A AR129995A1 (en) 2022-07-22 2023-07-21 ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES

Country Status (16)

Country Link
EP (1) EP4558528A1 (en)
JP (1) JP2025523995A (en)
KR (1) KR20250041021A (en)
CN (1) CN119654349A (en)
AR (1) AR129995A1 (en)
AU (1) AU2023312051A1 (en)
CA (1) CA3261989A1 (en)
CL (1) CL2025000179A1 (en)
CO (1) CO2025000447A2 (en)
CR (1) CR20250056A (en)
IL (1) IL317637A (en)
MA (1) MA71559A (en)
MX (1) MX2025000637A (en)
PE (1) PE20250796A1 (en)
TW (1) TW202417504A (en)
WO (1) WO2024020564A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019990A1 (en) * 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
ATE139900T1 (en) 1992-11-13 1996-07-15 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK1242438T3 (en) 1999-12-29 2007-02-12 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
HU231090B1 (en) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 The adorned cell of genome
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CA2481656A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
JP2005538722A (en) 2002-09-16 2005-12-22 エクセリクシス， インク． RORs as p21 pathway modifiers and methods of use
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005035586A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8219149B2 (en) 2005-06-29 2012-07-10 Nokia Corporation Mobile communication terminal
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060871A1 (en) 2006-05-09 2008-07-16 Genentech Inc UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
CN103694350B (en) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 Cross-species-specific cd 3-epsilon binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
PE20120540A1 (en) 2009-05-27 2012-05-09 Hoffmann La Roche THREE-SPECIFIC OR TETRA-SPECIFIC ANTIBODIES
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
KR101614195B1 (en) 2011-03-29 2016-04-20 로슈 글리카트 아게 Antibody fc variants
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RS56879B1 (en) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
WO2014165818A2 (en) * 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
HK1213578A1 (en) 2013-04-29 2016-07-08 豪夫迈‧罗氏有限公司 Human fcrn-binding modified antibodies and methods of use
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN105849124B (en) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 Dual specificity antibodies
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
JP6744292B2 (en) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
PE20170263A1 (en) 2014-08-04 2017-03-30 Hoffmann La Roche T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
JP6952605B2 (en) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド Multispecific antigen binding protein
HUE063270T2 (en) 2015-06-16 2024-01-28 Hoffmann La Roche Humanized and affinity matured antibodies to fcrh5 and methods of use
JP7633810B2 (en) * 2018-07-02 2025-02-20 アムジェン インコーポレイテッド Anti-STEAP1 antigen-binding protein
EP4025609A4 (en) * 2019-09-05 2023-10-04 Memorial Sloan Kettering Cancer Center ANTI-STEAP1 ANTIBODIES AND USES THEREOF
EP4072584B1 (en) * 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d antibodies and methods of use

Also Published As

Publication number Publication date
WO2024020564A8 (en) 2024-03-28
EP4558528A1 (en) 2025-05-28
JP2025523995A (en) 2025-07-25
KR20250041021A (en) 2025-03-25
WO2024020564A1 (en) 2024-01-25
CO2025000447A2 (en) 2025-02-04
MA71559A (en) 2025-05-30
CL2025000179A1 (en) 2025-06-06
IL317637A (en) 2025-02-01
CN119654349A (en) 2025-03-18
PE20250796A1 (en) 2025-03-14
AU2023312051A1 (en) 2025-01-09
CR20250056A (en) 2025-03-19
TW202417504A (en) 2024-05-01
MX2025000637A (en) 2025-03-07
CA3261989A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
PE20200862A1 (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS
HRP20220629T1 (en) Anti-cd73 antibodies and uses thereof
AR109535A2 (en) INHIBITING ANTIBODIES OF THE C-MET DIMERIZATION AND USES OF THE SAME
AR120741A1 (en) ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
PE20140848A1 (en) MONOCLONAL ANTIBODIES AGAINST RGMA PROTEIN AND ITS USES
RU2019123613A (en) BISPECIFIC ANTIGENBINDING MOLECULES CONTAINING ANTIBODY K4-1BB, CLONE 20N4.9
AR040046A1 (en) ANTI-IGFR HUMAN NEUTRALIZING ANTIBODY
CO6251370A2 (en) A HUMANIZED CD20 UNION MOLECULA THAT INCLUDES AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE DOMAIN (VH) AND A LIGHT IMMUNOGLOBULINE CHAIN VARIABLE DOMAIN (VL) AND SAME USE METHODS
RU2009136913A (en) BISPECIFIC BINDING AGENTS WITH INTER-SPECIFIC SPECIFICITY
RU2016145277A (en) ANTIBODY AGAINST IGF-1R AND ITS APPLICATION AS AN ADDRESSING CARRIER FOR TREATMENT OF CANCER
RU2014109039A (en) BSPECIFIC ANTIGEN BINDING MOLECULES
RU2013125459A (en) ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
PE20121647A1 (en) THERAPEUTIC BINDING PROTEINS TO DLL4
RU2008149918A (en) ANTIBODIES TO NKG2A AND THEIR APPLICATION
PE20230408A1 (en) ANTI-LILRB1 ANTIBODY AND USES THEREOF
RU2011103125A (en) Combination of c-Met antagonist and aminoheteroaryl for the treatment of cancer
PE20221256A1 (en) ANTIBODIES DIRECTED TO FLT3 AND USE THEREOF
PE20230844A1 (en) ANTI-NECTIN-4 ANTIBODY, CONJUGATE WHICH INCLUDES IT AND APPLICATION THEREOF
PE20240895A1 (en) ANTITRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
CN114667296A (en) A kind of bispecific antibody and use thereof
PE20240883A1 (en) ANTIBODIES CAPABLE OF BINDING CD27, VARIANTS AND USES THEREOF
AR129995A1 (en) ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES
PE20250390A1 (en) Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating ophthalmic or ocular diseases